Dyne Therapeutics, Inc. (NASDAQ:DYN) Receives Average Recommendation of “Buy” from Analysts

Dyne Therapeutics, Inc. (NASDAQ:DYN) has received a consensus recommendation of “Buy” from the eleven analysts that are covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a hold recommendation, nine have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $50.82.

A number of brokerages have recently commented on DYN. HC Wainwright reaffirmed a “buy” rating and issued a $55.00 price target on shares of Dyne Therapeutics in a research note on Wednesday, November 13th. Morgan Stanley upped their price target on Dyne Therapeutics from $48.00 to $52.00 and gave the company an “overweight” rating in a research note on Wednesday, August 14th. StockNews.com cut Dyne Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, September 16th. Guggenheim upped their price target on Dyne Therapeutics from $45.00 to $50.00 and gave the company a “buy” rating in a research note on Thursday, August 15th. Finally, Chardan Capital reaffirmed a “buy” rating and issued a $50.00 price target on shares of Dyne Therapeutics in a research note on Wednesday, November 13th.

Dyne Therapeutics Trading Up 4.5 %

Dyne Therapeutics stock opened at $29.44 on Thursday. Dyne Therapeutics has a 1 year low of $10.33 and a 1 year high of $47.45. The company has a market cap of $3.00 billion, a PE ratio of -8.27 and a beta of 1.09. The company’s 50-day moving average is $31.45 and its two-hundred day moving average is $35.49.

Dyne Therapeutics (NASDAQ:DYN) last released its earnings results on Tuesday, November 12th. The company reported ($0.96) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.25). Research analysts forecast that Dyne Therapeutics will post -3.45 EPS for the current year.

Insiders Place Their Bets

In other Dyne Therapeutics news, SVP Richard William Scalzo sold 1,390 shares of the company’s stock in a transaction that occurred on Wednesday, September 18th. The stock was sold at an average price of $34.55, for a total transaction of $48,024.50. Following the completion of the transaction, the senior vice president now owns 98,568 shares of the company’s stock, valued at $3,405,524.40. This represents a 1.39 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Carlo Incerti sold 16,500 shares of the company’s stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $28.73, for a total value of $474,045.00. The disclosure for this sale can be found here. Insiders sold a total of 176,257 shares of company stock valued at $6,193,718 in the last quarter. 20.77% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Dyne Therapeutics

Large investors have recently made changes to their positions in the stock. Nisa Investment Advisors LLC boosted its holdings in shares of Dyne Therapeutics by 904.1% in the 2nd quarter. Nisa Investment Advisors LLC now owns 743 shares of the company’s stock valued at $26,000 after buying an additional 669 shares during the last quarter. Quantbot Technologies LP acquired a new stake in shares of Dyne Therapeutics in the 3rd quarter valued at approximately $34,000. Point72 DIFC Ltd acquired a new stake in shares of Dyne Therapeutics in the 3rd quarter valued at approximately $36,000. US Bancorp DE boosted its holdings in shares of Dyne Therapeutics by 776.9% in the 3rd quarter. US Bancorp DE now owns 1,368 shares of the company’s stock valued at $49,000 after buying an additional 1,212 shares during the last quarter. Finally, Values First Advisors Inc. acquired a new stake in shares of Dyne Therapeutics in the 3rd quarter valued at approximately $62,000. Institutional investors and hedge funds own 96.68% of the company’s stock.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.